Introduction

The healthcare sector often grapples with the intricate web of regulations and guidelines that govern it. Ensuring compliance with these rules is not merely a legal obligation but also a cornerstone for maintaining public trust. A recent case involving Exagen Inc., a California-based life sciences company, underscores the importance of adhering to these standards and the repercussions of deviation.

Case Overview: Alleged Kickback Violations

Exagen Inc., renowned for its diagnostic tests that aid in treating autoimmune conditions, has recently concurred on a settlement amounting to $653,143. This settlement is in response to allegations that the company leveraged specimen processing fees to potentially influence physicians into using Exagen’s laboratory tests.

The backdrop of the case is as follows:

Exagen, as per the settlement’s factual admissions, had paid certain physicians for blood draw procedures concerning patients. These payments were made under specimen processing agreements that Exagen had with these physicians.

The gravity of the situation intensifies when one realizes that Exagen had billed federal healthcare programs, inclusive of Medicare and others, for the tests conducted post these orders from the aforementioned physicians. This, despite being privy to a June 25, 2014 Special Fraud Alert from the Department of Health & Human Services’ Office of the Inspector General (HHS-OIG). This alert explicitly cautioned laboratories about the probable substantial risk of fraud and abuse arising from the act of paying specimen processing fees to referring physicians.

The Role of the Whistleblower: Qui Tam Provisions

The genesis of this settlement can be traced back to a lawsuit initiated by a whistleblower. This lawsuit was based on the qui tam provisions of the False Claims Act. For those unacquainted, these provisions empower private individuals, labeled as relators, to sue on the government’s behalf. Furthermore, these relators are entitled to a share of any ensuing recovery.

In line with this, the whistleblower associated with the Exagen case will be receiving 16% of the recovery amount.

Conclusion: Lessons and Forward Path

The Exagen case provides a crucial lesson on the importance of strict adherence to compliance guidelines in the healthcare sector. Companies must be vigilant and proactive, especially when informed about potential pitfalls, as was the case with the 2014 Special Fraud Alert.

The scenario also accentuates the significant role whistleblowers play in maintaining checks and balances within the system. With the right mechanisms in place, and a renewed commitment to transparency and integrity, the healthcare industry can continue to serve the public while upholding the highest standards of compliance.

For more insights and legal perspectives on healthcare compliance, stay tuned to The Parrella Pulse: A Health Law Bulletin.